Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company that develops drug delivery formulations designed to improve the bioavailability of active pharmaceutical ingredients. Its primary technology, DehydraTECH, combines active molecules with fatty acid-rich triglyceride oils to facilitate absorption into the bloodstream through oral ingestion. The technology is utilized across pharmaceutical, nutraceutical, consumer packaged goods, and over-the-counter product categories, addressing indications such as diabetes, weight loss, hypertension, and epilepsy. Lexaria operates primarily by licensing its patented technology to corporate partners and industry participants who integrate DehydraTECH into developmental and commercial products, including oral pouches, capsules, tablets, foods, and beverages.

The company maintains an intellectual property portfolio of 56 granted or allowed patents worldwide, with active licensing agreements and operations extending across the United States, Australia, Japan, South Africa, and Europe. Lexaria conducts clinical research programs internationally, including clinical trials sponsored in Australia. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Lexaria Bioscience's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“The IND application was supported by the results of Lexaria’s five investigator-initiated human clinical studies of its DehydraTECH-CBD which were conducted between 2018-2023, in an aggregate total of 134 people, without recording a single serious adverse event (the “HYPER Studies”).”